At Moderna, we take corporate social responsibility (CSR) seriously. Our company policies and recent data demonstrate our commitment to transparency and serve to hold us accountable as we continue to develop potentially life-changing medicines.

We’re committed to optimizing the impact of mRNA vaccines and therapeutics through fair pricing and access for all.
Read Our Access Statement
Read Our IP Statement
As a company at the forefront of developing medicines for patients across the world, we have an obligation to purposefully uphold human rights.
Read Our Policy
We do not make direct contributions to political campaigns or candidates, and are committed to transparency on our engagement with trade associations and other advocacy organizations.
Ensuring all employees act ethically and legally in their business decisions and day-to-day duties is crucial to carrying out our mission.
We believe sound governance practices and policies are important to our success as a company and to obtaining the trust of our stakeholders.
Our 2018 Corporate Social Responsibility (CSR) whitepaper, which laid out the framework for the core focus areas of our CSR program.
We’ve pledged to act on supporting more inclusive workplaces because we know that success is rooted in diverse viewpoints.
Moderna team members drive our advancements toward bringing innovative medicines to patients. Our commitment to them is rooted in an inclusive environment that fosters well-being.
Learn more about how we have approached access and pricing for our COVID-19 vaccine, including as a result of government funding.

R&D investments
2018 | 2019 | 2020 | |
---|---|---|---|
R&D Expenses | $454 million | $496 million | $1,370 million |
R&D as a percentage of Total Operating Expenses | 83% | 82% | 87% |
Gender & ethnicity
2018 | 2019 | 2020 | |
---|---|---|---|
Percentage of workforce who are women | 44% | 46% | 46% |
Percentage of leadership (VP and above) who are women | 29% | 35% | 37% |
Percent of workforce who are racially/ethnically diverse (U.S. only) | 32% | 32% | 35% |